Why Ignoring CMC Early Can Cost You Millions
Biotech startups developing cell and gene therapies (CGT) often focus heavily on innovation—yet one of the biggest roadblocks to success is failing to plan for Chemistry, Manufacturing, and Controls (CMC) early enough. In fact, regulatory agencies like the FDA frequently issue clinical holds due to incomplete CMC data. How can you avoid these pitfalls and accelerate your path to clinical trials?